Pharmafile Logo
Pharmafocus logo
Advanced Search

Votrient

Showing 10 posts of 10 posts found.

Inlyta image

NICE backs Pfizer’s drug for advanced kidney cancer

December 16, 2014
Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo

UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …

News
Votrient image

‘More patients want Votrient’

April 2, 2014
Research and Development, Sales and Marketing Cancer, GSK, Pfizer, Sutent, Votrient

GlaxoSmithKline is looking at patient satisfaction as a potential marketing tool for its kidney cancer drug Votrient, setting up a …

News
Votrient image

GSK seeks licence extensions

August 8, 2013
Sales and Marketing Cervarix, EMA, GSK, Votrient

GlaxoSmithKline is seeking to extend the licences of two of its brands, Cervarix and Votrient, in a bid to extend …

News
votrient image

Survival boost for Votrient in mRCC

October 2, 2012
Research and Development, Sales and Marketing GSK, Nexavar, Pfizer, Sutent, Votrient

GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free …

News

GSK’s Votrient gains new licence

August 8, 2012
Sales and Marketing GSK, NICE, Votrient, soft cell sarcoma

GlaxoSmithKline has gained a new European licence for its cancer pill Votrient adding to its renal cell carcinoma licence. The …

News
Votrient image

FDA approves GSK’s Votrient for new licence

April 30, 2012
Sales and Marketing Cancer, FDA Approval, GSK, Votrient

The FDA has approved GlaxoSmithKline’s cancer pill Votrient for the treatment of a rare group of cancers – but has …

News

GSK’s patient access scheme for Votrient sways NICE

December 24, 2010
Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …

News

The renal cell carcinoma market: Votrient to challenge Sutent’s lead

November 25, 2010
Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma

After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …

Feature

GSK tipped to lead kidney cancer market

July 1, 2010
Sales and Marketing Kidney cancer, Patorma, Votrient, rcc

GlaxoSmithKline’s kidney cancer drug Votrient has been forecast as a future leader in a marketplace currently dominated by Pfizer. Analysts …

News

GSK’s Votrient approved in Europe

June 16, 2010
Sales and Marketing GlaxoSmithKline, Kidney cancer, Votrient

The European Commission has granted a conditional marketing authorisation for a GlaxoSmithKline drug that treats the most common form of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025